While biotech and pharma chase binary clinical trial results, the infrastructure, diagnostic and medical device giants quietly compound capital. They don't take drug-failure risks, they win simply because the volume of global medical procedures and testing increases due to aging demographics.
Investing in healthcare is often presented as a high-stakes gamble. The financial media loves to cover the dramatic binary events: a biotech startup soaring 200% on a positive Phase III FDA approval or a pharmaceutical giant losing billions overnight as a blockbuster drug falls off a patent cliff. But chasing those headlines is difficult and often risky, it is a game of roulette where the house always has the edge.
In this Thematic Ideas & Screeners report, we are ignoring the binary bets entirely. Instead, we are turning our Quality Stocks Investment Framework toward the ultimate pick-and-shovel operators of the healthcare universe.
For paid subscribers, we take the analysis one step further. Beyond identifying individual stock ideas, I apply the full Quality Stocks Investment Framework, including thematic screeners based on the Quality Stocks Score, fair value estimates, detailed Total Shareholder Return (TSR) breakdowns, defined buy zones and my investment verdict (Attractive / Conditional / Unattractive). This added layer is designed to bridge the gap between high-level insights and actual execution, helping long-term investors make more disciplined and risk-aware decisions.
If you enjoy Thematic Selections, be sure to check out the latest edition on Enterprise Software
Why Look at Medical Enablers Right Now?
Every long-term investor faces a core dilemma: how to position a portfolio for structural growth without overpaying for hype. For the last few quarters / years, the broader markets have been completely dominated by a narrow, high-multiple AI infrastructure trade. While tech multiples have expanded to historical premiums, the healthcare equipment and diagnostics sector has quietly lagged the broader market, creating an incredibly compelling setup for quality-focused investors.
There are several distinct reasons why this sector deserves a closer look
1. Structural Valuation Inefficiency
The financial market is currently suffering from a severe case of tunnel vision. Because capital has aggressively chased software and semiconductors, many elite MedTech and diagnostic compounders have experienced multi-year valuation compression.
Historically, companies like Idexx, Stryker or ThermoFisher command massive premium multiples because their earnings are highly predictable. Today, however, many of these stocks are trading near or below their 5-year historical average multiples (and often at the same valuation). When a high-quality business with structural moats experiences a valuation contraction while its underlying fundamentals continue to grow, it flashes a bright green light for our investment framework.
2. The Defensive Growth Cushion
We are operating in a macroeconomic environment where household purchasing power is showing visible signs of strain, credit delinquencies are ticking up and the cost of capital remains persistently high. In a slowing economy, discretionary consumer spending dries up.
The medical infrastructure basket benefits from non-discretionary demand. If a patient needs a heart valve replacement (Edwards Lifesciences), a continuous glucose monitor to prevent insulin shock (Dexcom) or an orthopedic joint replacement to maintain mobility (Stryker), the procedure happens regardless of GDP growth or interest rate hikes. This non-discretionary cushion gives these businesses bond-like defensive qualities during market downturns, while their commercial pricing power protects their high margins from inflationary pressures.
3. The Unstoppable Demographic Tailwind
Aside from their defensive resilience, the long-term compounding thesis for this sector is backed by the most predictable macroeconomic trend in existence: global aging.
By 2030, every single Baby Boomer will be over the age of 65. Statistically, the consumption of medical procedures, diagnostic testing and health monitoring scales exponentially as a population crosses this age threshold. The global medical device market alone is projected to nearly double, scaling toward a $1.2T market over the next decade.
By investing in the pick-and-shovel enablers, you are taking the underwriter’s position on this demographic shift. Whether a hospital is managing higher surgery throughput or a local vet clinic is running more senior pet screenings, the companies in our screener collect a toll on every single transaction.
4. High Switching Costs (The Clinical Ecosystem Lock-in)
In most industries, customers can jump to a competitor if a cheaper or slightly better option comes along. In healthcare, making a switch can be a logistical and regulatory nightmare.
Once an outpatient surgical center installs a specific set of equipment or a laboratory standardizes its testing workflows around a vendor like ThermoFisher, the cost of ripping out that infrastructure is prohibitive. It requires retraining entire nursing staffs, updating electronic health record (EHR) data integrations and re-validating strict compliance protocols.
Furthermore, surgeons develop experience with specific instruments. A hospital administrator cannot easily force an orthopedic surgeon to switch from a Stryker joint replacement system to a competitor just to save a few hundred dollars. The operational friction and clinical liability risk create a nearly unbreakable customer retention mechanism.
5. The Razor-and-Blades Lifeline (Forced Recurrence)
While tech companies boast about SaaS retention, elite medical enablers enjoy an even more reliable form of recurring revenue: legally mandated physical consumables.
Take Steris as a prime example. They sell the massive autoclaves and washing systems (the razor) used to clean surgical tools. Once installed, hospitals are legally required to purchase Steris’s proprietary chemical indicators, biological test packs, and sterilization wraps (the blades) to verify every single cleaning cycle. The hospital literally cannot operate without buying these refills.
Similarly, Dexcom derives roughly 91% of its revenue from its continuous glucose monitoring (CGM) patches. These sensors are hard-coded to automatically shut down after 10 to 15 days of use. The patient cannot choose to pause their subscription, they must open a new consumable patch, guaranteeing an automated re-order lifecycle.
6. Structural Secular Shift: The Migration to Outpatient Care
One of the most consequential structural shifts taking place across healthcare is the rapid migration of procedures out of legacy, high-cost hospitals and into Ambulatory Surgical Centers (ASCs) and outpatient clinics. Driven by changes in regulatory reimbursement frameworks, insurance providers are aggressively pushing complex orthopedic, spine and cardiac catheter procedures to these leaner facilities.
This transition is a massive catalyst for pick-and-shovel enablers. ASCs have entirely different economics than massive city hospitals, they require flexible, capital-light equipment setups. Companies like Steris and Stryker have adapted aggressively, shifting from selling outright heavy capital machinery to offering blended leasing, software bundling and subscription service contracts that match ASC operating budgets. This turns what used to be lumpier CAPEX sales into predictable operational revenue streams.
The 17 picks
To systematically screen these companies through our framework, we have broken down our watch list into 4 thematic sub-baskets based on their operational models and revenue drivers.
Basket 1: The Razor-and-Blades Consumable Powerhouses
These companies dominate the highest-margin segment of healthcare. They sell essential, single-use physical consumables that are automatically thrown away and re-ordered after a test, a medical procedure or a product manufacturing cycle.
Dexcom ($DXCM). The undisputed leader in continuous glucose monitoring (CGM). It boasts a roughly 91% recurring revenue profile driven by automated 10-to-15-day wearable sensor replacement cycles
West Pharmaceutical Services ($WST). The definition of a quiet monopoly. They manufacture the critical packaging components (the specific elastomer stoppers, seals and syringe plungers) required for almost every injectable biological drug and vaccine globally
Idexx Laboratories ($IDXX). The global king of veterinary diagnostics. They seed veterinary clinics with diagnostic machinery at low margins, then capture decades of high-margin recurring cash flow via proprietary on-site testing kits and assays
Sartorius Stedim Biotech ($DIM.PA). A core bioprocessing pure-play. They provide the single-use bioreactor bags, filters and fluid management systems that global biopharma companies rely on to safely grow and manufacture complex biologic drugs.
Senzime ($SEZI.ST). A hyper-focused Swedish micro-cap pioneer operating a textbook razor-and-blades model in the operating room. They manufacture the TetraGraph, a precision system used by anesthesiologists to monitor patient muscle paralysis depth during surgery. Backed by new global clinical mandates, Senzime frequently utilizes a capital-light hardware placement model in hospitals to bypass tight budget cycles, automatically unlocking high-margin recurring sales via their single-use disposable smart-sensors (TetraSens), which represent roughly 76% of net company revenue (and soon almost 90%)
Basket 2: Life Science Tools & Laboratory Infrastructure
The scientific gatekeepers. These companies provide the foundational analytical instruments, reagents and software that power global academic research, drug discovery and clinical trial pipelines.
Thermo Fisher Scientific ($TMO). The ultimate, scaled aggregator and manufacturer of life sciences tools. It acts as a non-discretionary one-stop-shop for clinical labs worldwide
Danaher ($DHR). An elite compounder operating a highly successful decentralized model, laser-focused on bioprocessing, diagnostics and high-barrier life science tools
Agilent ($A). A premier provider of precision analytical chemistry equipment, chromatography systems and mass spectrometry instruments used for strict quality control across pharma and industrial labs
Waters Corporation ($WAT). A liquid chromatography and high-performance analytical specialist that recently doubled its total addressable market by executing a massive merger with BD’s Biosciences division
Basket 3: High-Barrier MedTech & Interventional Implants
These are the premier engineering giants of the operating room. While their upfront equipment sales can experience macroeconomic cycles, their core revenue is highly predictable, backed by massive doctor switching costs, regulatory safety hurdles and intellectual property.
Boston Scientific ($BSX). A high-performing innovator dominating interventional cardiology, peripheral interventions and endoscopy, experiencing industry-leading organic revenue growth
Stryker ($SYK). The powerhouse of the orthopedic surgical ward, selling everything from the physical joint replacements to the robotic operating tables and power tools utilized by surgeons
Edwards Lifesciences ($EW). The undisputed global pioneer in structural heart therapies, controlling the lion’s share of transcatheter aortic valve replacements (TAVR)
Abbott Laboratories ($ABT). A highly diversified healthcare fortress spanning consumer nutrition, traditional diagnostics, and elite medical devices (such as the FreeStyle Libre glucose monitor)
Medtronic ($MDT). The legacy giant of medical devices. While it historically suffered from sluggish growth, it is undergoing an intense operational restructuring to streamline its portfolio and restore its compounding power
Basket 4: Specialized Monopolies & Ecosystem Niches
These players do not try to be everything to everyone. Instead, they completely control highly specific, mission-critical workflow niches within the healthcare ecosystem where competition is virtually non-existent.
Steris ($STE). A legal structural monopoly in infection prevention. They control the specialized radiation and autoclave facilities that hospital systems and pharma manufacturing plants are legally required to use to sterilize their tools and products
Resmed ($RMD). The global leader in cloud-connected sleep apnea treatment systems. They monetize a highly recurring ecosystem built on continuous digital patient monitoring software and ongoing replacement loops for consumer masks and tubes
Medistim ($MEDI.OL). A spectacular Nordic micro-cap monopoly that provides the specialized ultrasound imaging and transit time flow measurement (TTFM) probes used by cardiac surgeons to verify blood flow in real time during coronary artery bypass surgeries
The recurring revenue
As you know this is something I like. Here is the recurring revenue for each company
West Pharmaceutical ($WST). ~100% recurring | Every vial or syringe of injectable or biological drugs (including GLP-1s) requires their regulatory-validated elastomer stoppers and seals
Idexx Laboratories ($IDXX). ~91% recurring | In-clinic veterinary analyzers require continuous purchases of proprietary chemical diagnostic test kits and assays
Dexcom ($DXCM). ~91% recurring | Wearable continuous glucose monitors (CGMs) are hardcoded to expire, forcing patients to continually buy replacement physical sensors every 10 to 15 days
Steris ($STE). ~80% to 85% recurring | Hospitals are legally mandated to consume their specialized chemical indicators and sterility wraps during every single instrument sterilization cycle
Sartorius Stedim Biotech ($DIM.PA). ~75% to 80% recurring | Biomanufacturing lines use disposable plastic bioreactor bags and process filters that must be replaced after every single batch of biologic drugs
Senzime ($SEZI.ST). ~76% recurring (higher soon) | Their surgical muscle-paralysis monitors utilize zero-upfront placements, locking hospitals into buying proprietary, single-use patient smart-sensors for every operation
Resmed ($RMD). ~75% recurring | Natural degradation of plastic CPAP masks and tubing triggers insurance-subsidized replenishment cycles every 3 to 6 months, layered with digital SaaS patient-monitoring fees
Danaher ($DHR). ~70% to 75% recurring | Their massive global base of laboratory instruments requires a steady, continuous pull of proprietary bioprocess separation resins and testing reagents
Medistim ($MEDI.OL): ~68% recurring | Surgical workflows utilize a per-procedure usage smart-probe fee model, generating transaction-based recurring cash flows every time a cardiac bypass surgery occurs
Agilent ($A). ~66% recurring | Their installed analytical instruments require ongoing re-orders of specialty chromatography columns alongside long-term maintenance service contracts
ThermoFisher ($TMO). ~65% to 70% recurring | Acts as the non-discretionary partner for global labs, which must continually buy everyday catalog consumables and raw testing chemicals to remain operational
Waters Corporation ($WAT). ~55% to 60% recurring | High-performance liquid chromatography machines generate constant consumable demand for precision columns used in high-frequency pharmaceutical quality control
Abbott Laboratories ($ABT). ~50% to 55% recurring | Anchor-driven by rapid diagnostic test strips and the rolling consumable sales of their FreeStyle Libre continuous glucose monitor patches
Boston Scientific ($BSX). ~45% to 50% recurring | While implants are one-time events, procedures consume a highly predictable, single-use suite of delivery catheters, guidewires and mapping sensors that are thrown away immediately
Stryker ($SYK). ~40% to 45% recurring | Their robotic surgical systems (Mako) lock hospital groups into buying proprietary orthopedic replacement joints and single-use disposable attachments
Edwards Lifesciences ($EW). ~35% to 40% recurring | Hospital systems maintain predefined, rolling inventories of structural heart valves, triggering automatic re-orders from Edwards as patient surgeries consume them
Medtronic ($MDT). ~35% to 40% recurring | Driven by high-frequency surgical consumable loops, including diabetic insulin pump infusion sets, advanced vascular staplers and single-use cutting tips
Unlock the Full Analysis. For each of the 16 stocks, I apply the Quality Stocks Investment Framework in full:
Quality Score-based screener
Fair value estimates & detailed Total Shareholder Return (TSR) breakdowns
Defined buy zones
And a clear investment verdict: Attractive, Conditional or Unattractive
This is where insights turn into action
